Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma

Pazopanib is approved for treatment of advanced soft tissue sarcomas, but primary and secondary drug resistance limits its clinical utility. We investigated the molecular mechanisms mediating pazopanib resistance in human synovial sarcoma (SS) models. We found reduced cell sensitivity to pazopanib a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanzi, Cinzia, Dal Bo, Laura, Favini, Enrica, Tortoreto, Monica, Beretta, Giovanni Luca, Arrighetti, Noemi, Zaffaroni, Nadia, Cassinelli, Giuliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468361/
https://www.ncbi.nlm.nih.gov/pubmed/30909453
http://dx.doi.org/10.3390/cancers11030408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468361/
https://www.ncbi.nlm.nih.gov/pubmed/30909453
http://dx.doi.org/10.3390/cancers11030408

Ejemplares similares